PO136 Durable efficacy of cladribine tablets: clarity+extension

    loading  Checking for direct PDF access through Ovid

Abstract

Background

In CLARITY, cladribine tablets (CT) significantly reduced relapse rates in patients with relapsing multiple sclerosis. CLARITY Extension (EXT) compared the effects of 2 years’ additional CT treatment vs no additional treatment.

Objective

Assess efficacy of 2 courses of CT or placebo (PBO) in CLARITY and 2 additional courses of CT or PBO in EXT.

Methods

Patients receiving PBO in CLARITY were assigned to CT3.5 mg/kg; those treated with CT (3.5 or 5.25 mg/kg) were re-randomised 2:1 to CT3.5 mg/kg or PBO. Annualised relapse rates (ARR) and proportions qualifying relapse free (RF) were compared for CLARITY vs EXT within the same treatment groups: CT3.5 mg/kg in CLARITY and PBO in EXT (n=98); CT3.5 mg/kg in CLARITY and CT3.5 mg/kg in EXT (n=186); CT5.25 mg/kg in CLARITY and CT3.5 mg/kg in EXT (n=186); PBO in CLARITY and CT3.5 mg/kg in EXT (n=244).

Results

No significant differences in ARR for CLARITY vs EXT except for PBO in CLARITY and CT3.5 mg/kg in EXT (0.26 vs 0.10, p<0.0001). The proportion RF was similar between CLARITY vs EXT across groups and >70%, except for PBO in CLARITY and CT3.5 mg/kg in EXT (58.0% vs 79.6%, p<0.0001).

Conclusions

Clinical benefits were maintained in patients who received CT in CLARITY and PBO in EXT demonstrating durable efficacy.

Related Topics

    loading  Loading Related Articles